- Home
- VOR
as 05-30-2025 4:00pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 22.1M | IPO Year: | 2021 |
| Target Price: | $7.20 | AVG Volume (30 days): | 5.4M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.13 - $1.80 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vor Biopharma Inc. News
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
MT Newswires
22 days ago
Baird Downgrades Vor Biopharma to Neutral From Outperform
MT Newswires
22 days ago
Stifel Downgrades Vor Biopharma to Hold From Buy
MT Newswires
22 days ago
HC Wainwright Downgrades Vor Biopharma to Neutral From Buy
MT Newswires
23 days ago
Wedbush Downgrades Vor Biopharma to Neutral From Outperform, Adjusts Price Target to $0.40 From $7
GlobeNewswire
23 days ago
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Simply Wall St.
2 months ago
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely
GlobeNewswire
2 months ago
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
GlobeNewswire
4 months ago
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Compare VOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.